These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31486884)

  • 1. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
    Delcourt C; Gemival P; Nouhaud FX; Gobet F; Gillibert A; Ferlicot S; Sabourin JC; Irani J; Pfister C
    World J Urol; 2020 Jun; 38(6):1517-1524. PubMed ID: 31486884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
    Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
    Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
    Nam W; Chae HK; Jung Y; Kang H; Park M; Choi A; Park JY; Eom DW; Kim SJ
    Front Immunol; 2023; 14():1301510. PubMed ID: 38143745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.
    Damrauer JS; Roell KR; Smith MA; Sun X; Kirk EL; Hoadley KA; Benefield HC; Iyer G; Solit DB; Milowsky MI; Kim WY; Nielsen ME; Wobker SE; Dalbagni G; Al-Ahmadie HA; Olshan AF; Bochner BH; Furberg H; Troester MA; Pietzak EJ
    Clin Cancer Res; 2021 Aug; 27(16):4599-4609. PubMed ID: 34117034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OncoTherad
    Reis IB; Tibo LHS; de Souza BR; Durán N; Fávaro WJ
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5025-5036. PubMed ID: 36322290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
    Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
    Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Bedke J; Black PC; Szabados B; Guerrero-Ramos F; Shariat SF; Xylinas E; Brinkmann J; Blake-Haskins JA; Cesari R; Redorta JP
    Urol Oncol; 2023 Dec; 41(12):461-475. PubMed ID: 37968169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guérin in patients with non-muscle invasive bladder carcinoma: A retrospective study.
    Villoldo GM; Pombo MT; Aris M; Chemi J; Mandó P; Nagaraju S; Camean J; Burioni A; Egea D; Amat M; Mellado JL; Mordoh J; Villaronga A; Barrio MM
    Oncol Res; 2023; 31(2):207-220. PubMed ID: 37304240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer.
    Lebret T; Becette V; Hervé JM; Molinié V; Barré P; Lugagne PM; Gentille A; Baglin AC; Botto H
    Eur Urol; 2000 Jun; 37(6):654-9. PubMed ID: 10828663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Guérin Failure in Patients with Non-muscle-invasive Bladder Cancer.
    Strandgaard T; Lindskrog SV; Nordentoft I; Christensen E; Birkenkamp-Demtröder K; Andreasen TG; Lamy P; Kjær A; Ranti D; Wang YA; Bieber C; Prip F; Rasmussen J; Steiniche T; Birkbak N; Sfakianos J; Horowitz A; Jensen JB; Dyrskjøt L
    Eur Urol; 2022 Dec; 82(6):646-656. PubMed ID: 36210217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of various conservative treatment options with bacille Calmette-Guérin in bladder urothelial carcinoma T1G3: Maintenance therapy.
    Palou-Redorta J; Solsona E; Angulo J; Fernández JM; Madero R; Unda M; Martínez-Piñeiro JA; Portillo J; Chantada V; Moyano JL
    Actas Urol Esp; 2016; 40(6):370-7. PubMed ID: 26922518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
    Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
    Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.